Crizotinib-associated Renal Cyst Formation in a Pediatric Patient With ALK+ Epithelioid Inflammatory Myofibroblastic Sarcoma.

Authors :: Kopelevich A
Holzman SA
La J
Lai HA
Torno L
Stephany HA
Source :: Urology [Urology] 2021 Mar; Vol. 149, pp. 222-224. Date of Electronic Publication: 2020 Sep 01.
Publication Year :: 2021
Abstract: Background: Crizotinib is a first-generation tyrosine kinase inhibitor used for anaplastic lymphoma kinase (ALK) positive cancers. Simple and complex renal cyst formation is a rare complication of crizotinib use that has been reported previously in the adult population.<br />Case: We report a case of a right renal mass in a 17-year-old with ALK-positive epithelioid inflammatory myofibroblastic sarcoma treated with Crizotinib. After cessation of Crizotinib and initiating Alectenib, a second generation ALK inhibitor, the mass decreased in size and the patient remained asymptomatic without evidence of recurrence at three months of follow-up.<br /> (Copyright © 2020 Elsevier Inc. All rights reserved.)

Subjects :: Adolescent
Antineoplastic Agents therapeutic use
Crizotinib therapeutic use
Humans
Male
Neoplasms, Muscle Tissue chemistry
Neoplasms, Muscle Tissue drug therapy
Receptor Protein-Tyrosine Kinases analysis
Sarcoma chemistry
Sarcoma drug therapy
Antineoplastic Agents adverse effects
Crizotinib adverse effects
Kidney Diseases, Cystic chemically induced

Full Text Access

Tools